sulfamic acid [1-(2-methanesulfonamidoethyl)piperidin-4-yl]methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate

• ChemBase ID: 153132
• Molecular Formular: C19H29FN4O8S2
• Molecular Mass: 524.5839632
• Monoisotopic Mass: 524.14108413
• SMILES: COc1c(c2cc(ccc2[nH]1)F)C(=O)OCC1CCN(CC1)CCNS(=O)(=O)C.NS(=O)(=O)O
• Canonical SMILES: NS(=O)(=O)O.COc1[nH]c2c(c1C(=O)OCC1CCN(CC1)CCNS(=O)(=O)C)cc(cc2)F
• InChI: InChI=1S/C19H26FN3O5S.H3NO3S/c1-27-18-17(15-11-14(20)3-4-16(15)22-18)19(24)28-12-13-5-8-23(9-6-13)10-7-21-29(2,25)26;1-5(2,3)4/h3-4,11,13,21-22H,5-10,12H2,1-2H3;(H3,1,2,3,4)
• InChIKey: VQJFDBXITIOGJM-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: sulfamic acid [1-(2-methanesulfonamidoethyl)piperidin-4-yl]methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate
• IUPAC Traditional name: sulfamic acid [1-(2-methanesulfonamidoethyl)piperidin-4-yl]methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate
• Synonyms: [1-[2-[(Methylsulfonyl)amino]ethyl]-4-piperidinyl]methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate; GR 125487 sulfamate salt

Database IDs

• MDL Number: MFCD04039792
• PubChem SID: 162247272; 24278814
• PubChem CID: 6604955

CALCULATED PROPERTIES

• Acid pKa: 9.701829
• H Acceptors: 5
• H Donor: 2
• LogD (pH = 5.5): -1.0815774
• LogD (pH = 7.4): 0.6368942
• Log P: 1.0602351
• Molar Refractivity: 106.3664 cm^3
• Polarizability: 43.046032 Å^3
• Polar Surface Area: 100.73 Å^2
• Rotatable Bonds: 8
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: H2O: soluble ~14 mg/mL at 60 °C
• Apperance: off-white solid

Safety Information

• German water hazard class: 3
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• Storage Temperature: 2-8°C

Pharmacology Properties

• Gene Information: human ... HTR4(3360)

Product Information

• Purity: >98% (HPLC)
• Empirical Formula (Hill Notation): C19H26FN3O5S · SO3NH2

DETAILS

Sigma Aldrich - G6043

Biochem/physiol Actions
5-HT4 serotonin receptor antagonist.
Legal Information
Sold for research purposes under agreement from Glaxo-Smith-Kline